Incyte executive EVP & Chief Scientific Officer sells INCY shares

Incyte Corporation reported an insider stock sale by its Executive Vice President and Chief Scientific Officer.

Rhea-AI Filing Summary

Incyte Corporation reported an insider stock sale by its Executive Vice President and Chief Scientific Officer. On 12/10/2025, the officer sold 5,553 shares of common stock at $95.58 per share. On 12/11/2025, they sold another 255 shares at $94.94 per share. After these transactions, the reporting person directly beneficially owns 60,011 common shares. A footnote also identifies 59,858 additional shares of common stock issuable under previously reported restricted stock units that have not yet vested.

Insider Trade Summary

Net Seller: 5,808 shares

Net Sell 2 txns

Insider Mayes Patrick A

Role EVP & Chief Scientific Officer

Sold 5,808 shs ($555K)

Type	Security	Shares	Price	Value
Sale	Common Stock	255	$94.94	$24K
Sale	Common Stock	5,553	$95.58	$531K

Holdings After Transaction: Common Stock — 60,011 shares (Direct)

Footnotes (1)

1. F1. Includes an aggregate of 59,858 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Incyte (INCY) disclose in this filing?

An Executive Vice President and Chief Scientific Officer of Incyte Corporation reported open-market sales of common stock in two transactions on 12/10/2025 and 12/11/2025.

How many Incyte (INCY) shares did the executive sell and at what prices?

The executive sold 5,553 shares of common stock at $95.58 per share on 12/10/2025 and 255 shares at $94.94 per share on 12/11/2025.

How many Incyte (INCY) shares does the reporting person own after these sales?

Following the reported transactions, the reporting person directly beneficially owns 60,011 shares of Incyte common stock.

Does the Incyte (INCY) executive hold any restricted stock units?

Yes. A footnote states that there are 59,858 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

What is the reporting person’s role at Incyte (INCY)?

The reporting person is identified as an Officer, serving as EVP & Chief Scientific Officer of Incyte Corporation.

Is this Incyte (INCY) insider filing made by one or multiple reporting persons?

The document indicates that the Form is filed by one reporting person, not a group.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/12/2025 - 04:01 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mayes Patrick A

(Last) (First) (Middle)

1801 AUGUSTINE CUT-OFF

(Street)

WILMINGTON DE 19803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		S		5,553	D	$95.58	60,266	D
Common Stock	12/11/2025		S		255	D	$94.94	60,011(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes an aggregate of 59,858 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Remarks:

	/s/ Elizabeth Feeney, Attorney-In-Fact	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.